Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients

被引：0
|
作者：
Zhou, Z. [1 ]
Lu, S. [1 ]
Qin, S. [2 ]
Chen, J. [3 ]
Gu, K. [4 ]
Sun, P. [5 ]
Pan, Y. [6 ]
Yu, G. [7 ]
Ma, K. [8 ]
Shi, J. [9 ]
Sun, Y. [10 ]
Yang, L. [2 ]
Chen, P. [11 ]
Liu, A. [12 ]
He, J. [13 ]
Li, X. [14 ]
Wang, L. [14 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Lung Canc Ctr, Shanghai, Peoples R China
[2] Nanjing Jinling Hosp, Ctr Canc, Nanjing, Jiangsu, Peoples R China
[3] Hunan Canc Hosp, Oncol, Changsha, Hunan, Peoples R China
[4] Anhui Med Univ, Affiliated Hosp 1, Oncol, Hefei, Anhui, Peoples R China
[5] Yantai Yuhuangding Hosp, Oncol, Yantai, Peoples R China
[6] Anhui Prov Hosp, Oncol, Hefei, Anhui, Peoples R China
[7] Weifang Peoples Hosp, Oncol, Weifang, Peoples R China
[8] First Hosp Jilin Univ, Oncol, Jilin, Jilin, Peoples R China
[9] Linyi Canc Hosp, Oncol, Linyi, Shandong, Peoples R China
[10] Jinan Cent Hosp, Oncol, Jinan, Shandong, Peoples R China
[11] Yancheng First Peoples Hosp, Oncol, Yancheng, Peoples R China
[12] Nanchang Univ, Affiliated Hosp 2, Oncol, Nanchang, Jiangxi, Peoples R China
[13] Second Mil Med Univ, Stat, Shanghai, Peoples R China
[14] TOT BIOPHARM, Med, Suzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.382
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388P
引用
收藏
页码：S1393 / S1394
页数：2
相关论文
共 50 条
  • [1] Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study
    S. Lu
    S. Qin
    Z. Zhou
    J. Chen
    K. Gu
    P. Sun
    Y. Pan
    G. Yu
    K. Ma
    J. Shi
    Y. Sun
    L. Yang
    P. Chen
    A. Liu
    J. He
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5907 - 5914
  • [2] Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study
    Lu, S.
    Qin, S.
    Zhou, Z.
    Chen, J.
    Gu, K.
    Sun, P.
    Pan, Y.
    Yu, G.
    Ma, K.
    Shi, J.
    Sun, Y.
    Yang, L.
    Chen, P.
    Liu, A.
    He, J.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5907 - 5914
  • [3] Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
    Lima, Ellias Abreu
    Sales, Paulo Guilherme
    Vilaca, Israel
    Perillo, Fernanda
    Almeida, Flavia
    Martins, Graziella
    Goncalves, Mariana
    Toledo, Joseane
    Giovani, Poliana
    Silva, Wania
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1443 - S1444
  • [4] Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer
    Li, Cheryl S. W.
    Sweeney, Kevin
    Cronenberger, Carol
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 487 - 499
  • [5] Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer
    Cheryl S. W. Li
    Kevin Sweeney
    Carol Cronenberger
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 85 : 487 - 499
  • [6] Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
    Ko, Ryo
    Shukuya, Takehito
    Imamura, Chiyo K.
    Tokito, Takaaki
    Shimada, Naoko
    Koyama, Ryo
    Yamada, Kazuhiko
    Ishii, Hidenobu
    Azuma, Koichi
    Takahashi, Kazuhisa
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 183 - +
  • [7] Safety of Bevacizumab (Bv) in Superannuated Patients with Non-squamous Non-small Cell Lung Cancer
    Charpidou, Andriani
    Vassos, Dimitrios
    Tsimpoukis, Sotirios
    Demertzis, Panagiotis
    Gkiozos, Ioannis
    Syrigos, Kostas
    [J]. CHEST, 2014, 145 (03)
  • [8] A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
    Socinski, Mark A.
    Von Pawel, Joachim
    Kasahara, Kazuo
    Bondarenko, Igor
    Syrigos, Konstantinos
    Vladimirov, Vladimir Ivanovich
    Bryl, Maciej
    Zereu, Manuela
    Bair, A. H.
    Hilton, Fiona
    Liau, Katherine Faye
    Herbst, Roy S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] THE ADMINISTRATION OF BEVACIZUMAB FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES
    Fukunaga, Kentaro
    Kawashima, Satoru
    Yoshihashi, Saiko
    Seto, Ruriko
    Kanda, Rie
    Higami, Yuichi
    Goto, Kenichi
    Ryujin, Yasushi
    Nakagawa, Hiroaki
    Van Tho, Nguyen
    Yamaguchi, Masafumi
    Oguma, Tetuya
    Nagao, Taishi
    Ogawa, Emiko
    Nakano, Yasutaka
    [J]. RESPIROLOGY, 2013, 18 : 87 - 87
  • [10] Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)
    Tassinari, D.
    Drudi, F.
    Carloni, F.
    Nicoletti, S.
    Possenti, C.
    Santelmo, C.
    Lazzari, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345